Previous Article | Next Article 
Journal of Virology, May 2001, p. 4673-4680, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4673-4680.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Efficient Conversion of Normal Prion Protein (PrP)
by Abnormal Hamster PrP Is Determined by Homology at Amino Acid
Residue 155
Suzette A.
Priola,1,*
Joëlle
Chabry,2 and
Kaman
Chan3
Laboratory of Persistent Viral Diseases,
Rocky Mountain Laboratories, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Hamilton, Montana
598401; Department of Microbiology and
Immunology, Stanford University School of Medicine, Stanford,
California 94305-51243; and Institut de
Pharmacologie Moléculaire et Cellulaire CNRS, 06560 Valbonne-Sophia Antipolis, France2
Received 27 November 2000/Accepted 6 February 2001
 |
ABSTRACT |
In the transmissible spongiform encephalopathies, disease is
closely associated with the conversion of the normal proteinase K-sensitive host prion protein (PrP-sen) to the abnormal proteinase K-resistant form (PrP-res). Amino acid sequence homology between PrP-res and PrP-sen is important in the formation of new PrP-res and
thus in the efficient transmission of infectivity across species barriers. It was previously shown that the generation of mouse PrP-res
was strongly influenced by homology between PrP-sen and PrP-res at
amino acid residue 138, a residue located in a region of loop structure
common to PrP molecules from many different species. In order to
determine if homology at residue 138 also affected the formation of
PrP-res in a different animal species, we assayed the ability of
hamster PrP-res to convert a panel of recombinant PrP-sen molecules to
protease-resistant PrP in a cell-free conversion system. Homology at
amino acid residue 138 was not critical for the formation of
protease-resistant hamster PrP. Rather, homology between PrP-sen and
hamster PrP-res at amino acid residue 155 determined the efficiency of
formation of a protease-resistant product induced by hamster PrP-res.
Structurally, residue 155 resides in a turn at the end of the first
alpha helix in hamster PrP-sen; this feature is not present in mouse
PrP-sen. Thus, our data suggest that PrP-res molecules isolated from
scrapie-infected brains of different animal species have different
PrP-sen structural requirements for the efficient formation of
protease-resistant PrP.
 |
INTRODUCTION |
The transmissible spongiform
encephalopathy (TSE) diseases include scrapie in sheep and goats,
bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeldt-Jakob
disease in humans. A central pathogenic event in the TSE diseases
involves the mammalian prion protein (PrP). PrP is a
glycophosphatidylinositol (GPI)-anchored cell surface glycoprotein
present in many different tissues (1, 11, 30) but present
at particularly high levels in the brain (1). During the
course of TSE infection, normal host PrP-sen, a protein which is both
sensitive to digestion with proteinase K (PK) and detergent soluble, is
converted to an abnormal, detergent-insoluble form which is partially
resistant to PK digestion. This PK-resistant form of PrP, PrP-res,
accumulates to high levels in the lymphoreticular and central nervous
systems of the infected host. PrP-sen expression and PrP-res
accumulation are both believed to be involved in the neurodegeneration
which leads to the characteristic spongiform changes in the brains of
infected animals (8). The close association of PrP-res
with infectivity and the lack of any well-documented bacterial or viral
association with TSE diseases have led to the hypothesis that PrP-res
itself is the infectious agent (35). Although this
hypothesis has yet to be proven, PrP-res and PrP-sen clearly play
important roles in disease pathogenesis (4, 8, 9).
With the TSE diseases, there can be a strong barrier to infection of
one animal species with the TSE agent of a different species. This
resistance is manifested either as a long disease incubation time upon
primary passage in the host animal or as a lack of clinical disease
altogether. Species barriers in TSE diseases are of particular
importance given the probability that BSE has crossed species barriers
to cause variant Creutzfeldt-Jakob disease in humans in the United
Kingdom (50). In the United States, the possibility exists
that chronic wasting disease, a TSE identified for wild and captive
populations of deer and elk in several western states (51,
52), could cross species barriers to infect range cattle and
potentially expose the human population to a new TSE infection. Thus,
it is important to understand the mechanisms underlying species
barriers to infection with the TSE diseases and to determine how to
prevent cross-species transmission of TSE infection.
Studies with transgenic mice have shown that the sequence of PrP
influences the interspecies transmission of TSE infection between mice
and Syrian hamsters (45, 46) and between humans and mice
(49). In these studies, amino acid sequence homology between host PrP-sen and PrP-res associated with the incoming TSE agent
appeared to be necessary for the efficient transmission of TSE
infection across species (36, 45). Homology in the middle
portion of the PrP molecule was particularly important (27, 34,
46, 47). Therefore, at the molecular level, TSE species barriers
can be at least partly explained by the dependence of PrP-res formation
on PrP amino acid sequence homology.
In vitro studies with mouse neuroblastoma cells persistently infected
with mouse scrapie (Sc+-MNB cells) have
demonstrated that protease-resistant PrP formation can be extremely
sensitive to even minor differences between the PrP-sen and the PrP-res
amino acid sequences (24, 32, 34, 46). In
Sc+-MNB cells, substitution of the mouse-specific
isoleucine with a hamster-specific methionine at residue 138 in mouse
PrP-sen significantly inhibited the species-specific formation of mouse PrP-res (34). Interestingly, an isoleucine-to-methionine
substitution occurs naturally at the equivalent residue (position 142)
in goat PrP and is associated with resistance to both sheep scrapie and BSE infection, as indicated by a significant increase in disease incubation time (18). Thus, the same polymorphism at a
single amino acid residue has been shown to have an effect on PrP-res formation in vitro and on cross-species transmission of TSE infection in vivo. This finding suggests that, for some animal models of scrapie,
a mismatch at this amino acid residue between host PrP-sen and
TSE-associated PrP-res could interfere with the transmission of TSE
infection across species barriers.
In order to determine if homology at amino acid 138 also mediated
PrP-res formation in other species, both Sc+-MNB
cells and a cell-free model of protease-resistant PrP formation were
used to determine the amino acid residues necessary for the formation
of hamster PrP-res. Our data show that homology at amino acid residue
155, not at the hamster equivalent of mouse PrP residue 138 (i.e.,
hamster PrP residue 139), is necessary for the efficient formation of
protease-resistant hamster PrP. Residue 155 is located in a structural
region of PrP different from that in which residue 139 is located.
Therefore, our data suggest that PrP-res molecules isolated from
different species of TSE-infected animals have different PrP-sen
structural requirements for inducing the formation of more PrP-res.
Consequently, there is no single amino acid position which acts
similarly in all species to allow the cross-species formation of
PrP-res.
 |
MATERIALS AND METHODS |
Cells.
Sc+-MNB cells have been
described previously (38, 39). These cells express mouse
PrP-sen, accumulate mouse PrP-res, and replicate the mouse scrapie
agent (38). The retrovirus packaging cell lines
PA317 and
2 have been described previously (43).
Antibodies.
The anti-hamster PrP-specific mouse monoclonal
antibody 3F4 recognizes within hamster PrP an epitope which includes
the hamster-specific methionines at positions 109 and 112 (5,
25). Normal mouse PrP-sen is not recognized by the antibody 3F4
(25). Substitution of the leucine and valine residues at
the equivalent mouse positions (residues 108 and 111) with
methionine results in the expression of the 3F4 epitope in mouse PrP
(16). All of the recombinant hamster and mouse PrP-sen
molecules used in this study expressed this antibody epitope. The
anti-PrP peptide rabbit polyclonal antibody R.30 was raised to a PrP
peptide encompassing residues 89 to 103 and recognizes both mouse PrP
and hamster PrP (15).
Clones.
Mouse PrP-sen mutated to contain the 34F antibody
epitope and a unique NaeI restriction endonuclease site
(Mo3F4) and normal hamster PrP with a unique BstEII
restriction endonuclease site have been described previously (16,
34). Mo3F4 clones containing amino acid mutations at residues
138, 154, and 169 were derived using a series of 10 overlapping
oligonucleotides containing the desired mutations (34).
These oligonucleotides spanned the region of Mo3F4 from the
NaeI site to the BstEII site (nucleotides 436 to
660). For Mo3F4 without the GPI anchor
[Mo3F4(GPINEG)], the GPI anchor addition site
was removed by inserting a stop codon at residue 231 and deleting
C-terminal amino acid residues 232 to 254 (26). Clones
with the Mo3F4(GPINEG) background are designated
by a three-letter code. Each letter represents the amino acid present
at residue 138, 154, or 169, respectively (see Fig. 2).
Hamster PrP mutated at position 155 was derived by subcloning
the NaeI-BstEII fragment of the mutant
Mo3F4(GPINEG) construct MYN (see Fig. 2) into
hamster PrP containing a unique BstEII site
(34). All recombinant PrP-sen molecules were subcloned into the retrovirus expression vector pSFF and transfected into a 1:1
mixture of the retrovirus packaging cell lines PA317 and
2
(10, 32). These cells were used both as a source of
recombinant PrP-sen and as a source of infectious retrovirus encoding
recombinant PrP-sen.
Analysis of recombinant PrP-sen and PrP-res in
Sc+-MNB cells.
Sc+-MNB cells
were transduced with PA317 and
2 tissue culture supernatants
containing infectious retroviruses encoding recombinant PrP-sen
molecules (10, 32). Following transduction, cell surface immunofluorescence with antibody 3F4 showed that 80 to 100% of the
Sc+-MNB cells expressed the transduced PrP-sen
mutants (data not shown). Cells were also analyzed for recombinant PrP
expression by radiolabeling with
35S-methionine-cysteine
(Tran35S; NEN) followed by immunoprecipitation
using the hamster-specific 3F4 antibody epitope as previously described
(13, 32). In Sc+-MNB cells, the 3F4
antibody epitope allows exogenous recombinant PrP-sen to be
distinguished from endogenous mouse PrP-sen and mouse PrP-res
molecules, which do not contain the 3F4 epitope (32, 47).
Following PK treatment, PrP-res derived from the exogenous PrP-sen
mutants was detected by Western blotting with antibody 3F4, while
PrP-res derived from both endogenous and exogenous PrP-sen was detected
with the anti-PrP peptide rabbit polyclonal antibody R.30 (26,
32). Western blots were developed with the enhanced
chemiluminescence system (Amersham) as specified by the manufacturer.
Cell-free conversion assays.
The contents of flasks (25 cm2) of a confluent
2-PA317 cell culture
expressing the desired recombinant PrP-sen were labeled with 1.5 mCi of
Tran35S as described previously (10,
26). PrP-res was purified from brains of Syrian hamsters
infected with the hamster scrapie strain 263K or VM/DK mice infected
with the mouse scrapie strain 87V (10, 20). The in vitro
conversion of PrP-sen to protease-resistant PrP has been described
elsewhere (10, 26). Briefly, 200 ng of guanidine
hydrochloride-treated PrP-res was mixed with 20,000 cpm (~2 ng) of
radiolabeled, immunoprecipitated PrP-sen. The reaction mixture was
incubated at 37°C for 2 days. After incubation, 10% of the reaction
mixture was precipitated in methanol (total PrP). The remaining 90%
was treated with 12 µg of PK/ml for 1 h at 37°C. PK was
inactivated by the addition of protease inhibitors, and the protein was
methanol precipitated (PrP-res). Radiolabeled protease-resistant
products were analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The amounts of protease-resistant and
protease-sensitive proteins were determined using a Molecular Dynamics
Storm PhosphorImager system. Bands were quantified in terms of the
integrated peak volume, and the percent conversion was calculated using
the following formula: [(volume of PrP-res/volume of total
PrP)(10)] × 100. The percent relative conversion was determined by
comparing the level of conversion of hamster PrP-sen to that of
mutant PrP-sen using the following formula: (percentage of mutant
PrP-sen converted/percentage of hamster PrP-sen converted) × 100.
 |
RESULTS |
Homology at amino acid residue 139 is not sufficient for hamster
PrP-res formation in Sc+-MNB cells.
It was previously
shown that the conversion of Mo3F4 PrP-sen by mouse PrP-res in
Sc+-MNB cells was strongly dependent upon amino
acid homology at position 138 (34). In order to determine
if homology at the same position in hamster PrP-sen would allow its
conversion by mouse PrP-res, the hamster-specific methionine at the
equivalent hamster residue 139 was replaced with the mouse-specific
isoleucine. The resultant mutant, HaPrP-I139, was expressed in
Sc+-MNB cells and assayed for its ability to
convert to PrP-res. When expressed at similar levels (Fig.
1A), neither HaPrP-I139 nor wild-type
hamster PrP-sen was converted to PrP-res (Fig. 1B). Therefore, a
mouse-specific isoleucine at position 139 was not sufficient to allow
the cross-species conversion of hamster PrP-sen by mouse PrP-res.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 1.
Hamster PrP with a mouse-specific isoleucine at position
139 is not converted to PrP-res in Sc+-MNB cells. (A)
Analysis of PrP-sen expression in Sc+-MNB cells transduced
with the designated PrP-sen construct by radioimmunoprecipitation with
antibody 3F4 (13, 32). The exposure time was 5 days.
HaPrP, hamster PrP. (B) Analysis of PrP-res derived from the indicated
3F4 antibody epitope-positive recombinant PrP-sen constructs by Western
blotting with antibody 3F4. Of the transduced constructs, only Mo3F4
PrP-sen was converted to PrP-res. (C) Analysis of overall
PrP-res levels from endogenous and mutant PrP-res molecules in
Sc+-MNB cells by Western blotting with the rabbit anti-PrP
polyclonal antibody R.30. For all panels, the brackets and arrows on
the left indicate PrP-specific bands and molecular mass markers in
kilodaltons are shown on the right. The upper arrow in panel A
designates the PrP dimer expressed by hamster PrP-sen
(33). All data are from the same experiment, which was
repeated five times. Extra lanes were excised from the gels for the
purpose of data presentation. Mock, Sc+-MNB cells not
expressing any exogenous 3F4-reactive PrP-sen.
|
|
Previous experiments have shown that introduction of the 3F4 epitope
into mouse PrP-sen (i.e., a methionine at amino acid
residues 108 and
111) can interfere with the formation of PrP-res
from endogenous mouse
PrP-sen in Sc
+-MNB cells (
32). If
the level of expression of recombinant 3F4
epitope-containing PrP-sen
is high enough, no PrP-res can be detected
(
31,
32). Since
all of the constructs tested contained the
3F4 epitope, the lack of
conversion of HaPrP-I139 to PrP-res in
Sc
+-MNB
cells could be explained simply by a shutdown in PrP-res
formation. In
order to determine if Sc
+-MNB cells expressing
HaPrP-I139 still accumulated PrP-res, overall
PrP-res levels were
assayed by Western blotting using the rabbit
polyclonal antibody R.30.
This antibody detects both endogenous
and recombinant PrP molecules.
Endogenous mouse PrP-res was still
detectable, albeit at low levels, in
Sc
+-MNB cells expressing HaPrP-I139 (Fig.
1C).
However, even in experiments
where little or no interference with
endogenous mouse PrP-res
formation was observed,
protease-resistant HaPrP-I139 was never
detected (data not
shown). Thus, the inability of HaPrP-I139 to
be converted to protease
resistance was not a consequence of a
shutdown in total PrP-res
formation in Sc
+-MNB cells. Overall, our results
suggest that homology at amino
acid residues other than 138 is
necessary for hamster PrP-sen
to be converted to PrP-res.
Homology at amino acid residue 155 influences the formation of
protease-resistant hamster PrP.
In the region of PrP which has
been shown to influence the species-specific formation of PrP-res
(amino acids 112 to 188) (27, 34, 47), there are three
differences between mouse PrP and hamster PrP, at mouse and hamster
residues 138 and 139, 154 and 155, and 169 and 170, respectively
(29). The formation of hamster PrP-res therefore could be
dependent upon homology at a residue(s) other than position 139. Since
tissue culture cells persistently infected with hamster scrapie are not
available, we used a cell-free conversion system (26) to
assay the ability of PrP-res derived from the brains of scrapie strain
263K-infected hamsters to convert a panel of radiolabeled PrP-sen
molecules which had been mutated at the three variant residues (Fig.
2).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Structures of recombinant PrP-sen (GPINEG)
molecules. The top line shows the secondary structure of processed
mouse PrP-sen (PrP-sen23-231) (23). The line
designates turns and loops or disordered structure, the small gray
boxes indicate areas of beta strands, and the hatched boxes indicate
alpha helices. The N-linked glycosylation sites are indicated by
lollipops. The GPI anchor is indicated on the right. The region of PrP
from mouse residues 108 to 188, associated with the species-specific
formation of PrP-res (27, 34, 47), is expanded below.
White bars represent mouse PrP sequence, and black bars represent
hamster PrP sequence. The two methionines at mouse and hamster PrP
positions 108 and 109 and positions 111 and 112, respectively, which
comprise the 3F4 antibody epitope, are indicated. The three variant
amino acid residues between mouse PrP and hamster PrP at mouse and
hamster positions 138 and 139, 154 and 155, and 169 and 170, respectively, are indicated. Residues shaded in black are specific to
hamster PrP, while nonshaded residues are specific to mouse PrP. Clone
designations are shown on the left.
|
|
Since N-linked glycans are not required for PrP-res formation in the
cell-free reaction (
26,
41), recombinant PrP-sen
molecules
from which the GPI membrane anchor had been removed
(GPI
NEG) were initially used in our mapping
studies (
26). Glycosylation
is drastically reduced in
GPI
NEG clones. As a result, these PrP molecules
yield species-specific,
appropriately sized, and easily identified
conversion products
in the cell-free conversion assay
(
26). All GPI
NEG clones contained
the mouse PrP amino acid sequence, except that
hamster-specific
residues were present at positions 108 and 111
(the 3F4 epitope) and/or
at positions 138, 154, and 169 (Fig.
2). Amino acid homology in regions
of PrP-sen other than at residues
112 to 188 has been shown to have
little or no influence on the
species-specific formation of PrP-res
(
27,
34,
47). Thus,
Mo3F4(GPI
NEG)
PrP-sen with hamster PrP-specific residues from 108 to 188 (clone
MNN)
(Fig.
2) was converted to protease-resistant PrP by hamster
PrP-res as
efficiently as the homologous GPI
NEG hamster
clone [clone MNN(HaPrP)] (Fig.
3B,
compare lanes 8 and
9). Therefore, we initially used mutations in the
Mo3F4(GPI
NEG) background to map the critical
amino acid residues in hamster
PrP-res-mediated conversions.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 3.
Homology at mouse PrP-sen amino acid residue 154 is
important for hamster PrP-res-induced formation of protease-resistant
PrP. (A to C) Lanes 1 to 8, formation of protease-resistant PrP from
mutant Mo3F4(GPINEG) PrP-sen molecules; lane 9, GPINEG recombinant hamster PrP-sen. The name of the clone
is indicated above each lane. Molecular mass markers in kilodaltons are
indicated on the right. In panel A, 10% of the total reaction mixture
without PK treatment but in the presence of 263K-derived hamster
PrP-res was used. The input amount of radiolabeled recombinant PrP was
equivalent for each reaction. The PrP bands which were quantified are
indicated by the bracket on the left. In panel B, the remaining 90% of
the reaction mixture from panel A following digestion with PK was used.
The correctly sized protease-resistant PrP bands (26)
which were quantified are indicated by the bracket on the left. In
panel C, in the absence of 263K-derived hamster PrP-res, no
protease-resistant products remained following PK digestion. (D)
Percent relative conversion of the recombinant PrP-sen molecules from
panel B. The graph represents data from 11 to 13 samples from several
independent experiments. The percentage of homologous
GPINEG hamster PrP converted to protease-resistant PrP by
hamster PrP-res was set to 100% and compared to the amount of
protease-resistant product formed by the heterologous PrP-sen mutants.
This value, designated the percent relative conversion, as detailed in
Materials and Methods, is shown on the left. The constructs tested are
indicated below the graph. Error bars represent the standard error of
the mean. Constructs for which results were significantly different
from the homologous conversion of GPINEG hamster PrP at a
P value of 0.01 are denoted by double asterisks, while
a P value of 0.05 is denoted by a single asterisk.
Statistical analysis was performed using a one-way repeated-measures
analysis of variance with Dunnett's post test.
|
|
For all of the Mo3F4(GPI
NEG) mutants tested (Fig.
3A), the formation of protease-resistant PrP was always dependent upon
the
addition of 263K-derived hamster PrP-res (Fig.
3C). Mouse-specific
amino acid residues at position 138 or 169 did not affect the
hamster
PrP-res-mediated conversion of PrP-sen (Fig.
3B, compare
lanes 5 and 7 to lane 8). However, when a mouse-specific tyrosine
was substituted for
the hamster-specific asparagine at position
154, the level of
protease-resistant PrP generated dropped significantly
(Fig.
3B,
compare lanes 6 and 8). Although the formation of protease-resistant
PrP was never completely abolished, the effect of a tyrosine at
residue
154 reproducibly reduced the formation of protease-resistant
PrP by
two- to fourfold regardless of homology at residues 138
and 169 (Fig.
3D). For example, Mo3F4(GPI
NEG)
PrP-sen with a hamster-specific asparagine at position 154 but
mouse-specific residues at positions 138 and 169 was converted
to
protease-resistant PrP as efficiently as GPI
NEG
hamster PrP-sen (Fig.
3B, compare lanes 2 and 9, and Fig.
3D).
Hamster
PrP-res therefore requires homology at residue 154 (residue
155 in hamster PrP-sen) to efficiently convert PrP-sen to
protease-resistant
products.
Amino acid residue 155 affects protease-resistant PrP formation in
wild-type hamster PrP-sen.
Normal PrP-sen is located at the cell
surface and is inserted into the cell membrane via a GPI membrane
anchor (12, 48) which may influence PrP-res
formation. In order to determine if homology at residue 154 also
affected protease-resistant PrP formation from GPI anchor-positive
(GPIPOS) hamster PrP-sen (i.e., wild-type hamster
PrP), GPIPOS hamster PrP-sen with a
mouse-specific tyrosine at hamster residue 155 (HaPrP-Y155) was tested
with the cell-free conversion assay. The efficiency of conversion of
HaPrP-Y155 induced by hamster PrP-res was significantly lower than that
of wild-type hamster PrP-sen (Fig. 4A,
right panel). Furthermore, the pattern of the protease-resistant
products was different from that of GPIPOS
hamster PrP-sen and indistinguishable from that of
Mo3F4(GPIPOS) PrP-sen (Fig. 4A, right panel).
Thus, a mismatch at position 155 is important both qualitatively and
quantitatively (Fig. 4C) in the formation of protease-resistant PrP
from wild-type hamster PrP.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 4.
Efficient conversion of GPIPOS PrP-sen
mutated at amino acid residue 154 or 155 is dependent upon the species
of PrP-res. (A and B) Cell-free conversion of mutant
(GPIPOS) mouse or hamster PrP-sen by PrP-res derived from
scrapie-infected hamster (A) or mouse (B) brains. In each panel, the
names of the radiolabeled PrP-sen molecules are indicated above the
lanes. HaPrP, hamster PrP. The left panels show 10% of the total
reaction mixture without PK treatment but in the presence of the
indicated PrP-res constructs and demonstrate that the input amounts of
radiolabeled PrP in the reactions were equivalent. The PrP bands which
were quantified are indicated by the brackets on the left. The right
panels show the remaining 90% of the reaction mixture following
digestion with PK. The PrP-res bands which were quantified are
indicated by the brackets on the left. The formation of
protease-resistant PrP was dependent upon the addition of PrP-res (data
not shown). Molecular mass markers in kilodaltons are indicated on the
right. Extra lanes were excised from the gels for the purpose of data
presentation. (C) Data from four independent repeats of the experiments
in panels A and B. Error bars indicate the standard error of the mean.
Statistical analysis was performed using a one-way repeated-measures
analysis of variance with Dunnett's post test; double asterisks
indicate a P value of <0.001.
|
|
Homology at amino acid residue 154 does not influence mouse
PrP-res-mediated cell-free conversions.
In
Sc+-MNB cells, amino acid residue 154 did not
appear to significantly influence mouse PrP-res formation
(34). This finding suggested that the strong negative
effect of a mismatch at this residue was specific to conversions
induced by 263K-derived hamster PrP-res. In order to determine if this
was the case, a hamster-specific asparagine was substituted for the
mouse-specific tyrosine in GPIPOS Mo3F4 PrP-sen
(Mo3F4-N154). PrP-res derived from the brains of mice infected with
mouse strain 87V converted Mo3F4-N154 almost as efficiently as
wild-type Mo3F4 (Fig. 4B, right panel) but converted GPIPOS hamster PrP-sen poorly (Fig. 4B, right
panel, and Fig. 4C). Thus, consistent with the results for
Sc+-MNB cells (34), the formation of
protease-resistant PrP by mouse PrP-res was not influenced by
homology at residue 154 (residue 155 in hamster PrP).
 |
DISCUSSION |
We have shown that amino acid residue 155 in hamster PrP-sen is
critically involved in the species-specific induction of
protease-resistant PrP formation by hamster PrP-res. This residue is
different from those which have been identified in species barriers to
infection for other animal TSE diseases, including those of mice
(34), goats (18), humans (41),
and sheep (6, 7, 41). Our data suggest that different
species of PrP-res have different amino acid sequence homology
requirements for the efficient formation of protease-resistant PrP.
Thus, it is likely that there is no universal amino acid residue in PrP
which acts similarly in all PrP species as a "switch" to allow
cross-species formation of PrP-res.
Several different studies have shown that efficient cross-species
transmission of TSE infection between mice and Syrian hamsters can be
affected by homology at certain amino acid residues between the PrP-sen
of the mouse and the PrP-res associated with the incoming hamster
scrapie agent (36, 45, 46). In our studies, the negative
effect of a mismatch at position 155 did not lead to the complete
abolition of protease-resistant PrP formation. This result suggests
that in vivo, a mismatch at residue 155 between mouse PrP-sen and
hamster PrP-res would not be absolutely protective but might simply
delay disease development. Consistent with this prediction, recent
studies have shown that mice infected with hamster scrapie propagate
the scrapie agent (37), eventually begin to
accumulate PrP-res, and develop clinical disease after extremely long
incubation times (19). Our data provide an explanation at
the molecular level for these results. Inefficient conversion of mouse
PrP-sen to mouse PrP-res by the incoming hamster agent is strongly
influenced by homology at amino acid residue 155, which could be
responsible, at least in part, for the strong, but not absolute, TSE
species barrier between mice and Syrian hamsters.
The precise mechanism by which position 155 affects protease-resistant
PrP formation is unclear. At least two broadly defined and sequential
events occur during the formation of PrP-res: (i) PrP-PrP binding and
(ii) conversion (2, 17, 21). One analysis of the hamster
PrP-sen nuclear magnetic resonance structure suggested that the
difference between a mouse-specific tyrosine and a hamster-specific asparagine at position 155 would have little structural effect (28), while another predicted that changes at position 155 might modify the specificity of intermolecular interactions
(3). Thus, a mismatch at position 155 could affect
protease-resistant PrP formation by interfering with the specific
binding of PrP-sen to PrP-res. Although our data are consistent with
this possibility, residue 155 is outside of the region of PrP recently
implicated in the initial interaction of PrP-sen with PrP-res
(21). Furthermore, heterologous PrP-sen and PrP-res
molecules appear to bind as efficiently as homologous PrP molecules
(22; S. Priola, unpublished data), suggesting that
a mismatch at residue 155 would have little effect. Therefore, if amino
acid residue 155 has an influence on PrP-PrP binding, it would occur at
an as-yet-unidentified inter- or intramolecular PrP-PrP interaction
which follows the initial binding event.
Unlike the initial binding between PrP-sen and PrP-res, the conversion
of PrP to protease resistance is very sensitive to changes in the PrP
amino acid sequence (6, 7, 40, 41). Amino acid residue 155 is variable between mice and hamsters, a difference which is probably
responsible for one minor change in secondary structure between the two
molecules. In mouse PrP-sen, the tyrosine at 154 is at the C-terminal
end of the first alpha helix (23, 42), while in hamster
PrP-sen, residue 155 is an asparagine which forms a hydrogen-bonded
turn at the end of the first alpha helix (28). If residue
155 influences a conversion event which follows the initial binding of
PrP-sen to PrP-res, our data would suggest that this hydrogen-bonded
turn is important in the efficient conversion of PrP to protease
resistance induced by hamster PrP-res but not mouse PrP-res. This
requirement for a hydrogen-bonded turn is different from the structural
requirement for mouse PrP-res formation in which loop structures appear
to be important (31, 34). That PrP-res molecules isolated
from mouse or hamster scrapie-infected animals have different
PrP-sen structural requirements is consistent with the different
PrP-res conformations associated with these animal models of scrapie
(14, 44).
 |
ACKNOWLEDGMENTS |
We thank Bruce Chesebro for making the GPINEG
versions of our mutant mouse PrP molecules. We also thank Byron
Caughey, Ina Vorberg, Bruce Chesebro, Kim Hasenkrug, and Karin Peterson
for suggestions on and critiques of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Persistent Viral Diseases, Rocky Mountain Laboratories, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, 903 South 4th St., Hamilton, MT 59840. Phone: (406)
363-9264. Fax: (406) 363-9286. E-mail: spriola{at}nih.gov.
 |
REFERENCES |
| 1.
|
Bendheim, P. E.,
H. R. Brown,
R. D. Rudelli,
L. J. Scala,
N. L. Goller,
G. Y. Wen,
R. J. Kascsak,
N. R. Cashman, and D. C. Bolton.
1992.
Nearly ubiquitous tissue distribution of the scrapie agent precursor protein.
Neurology
42:149-156[Abstract/Free Full Text].
|
| 2.
|
Bessen, R. A.,
D. A. Kocisko,
G. J. Raymond,
S. Nandan,
P. T. Lansbury, Jr., and B. Caughey.
1995.
Nongenetic propagation of strain-specific phenotypes of scrapie prion protein.
Nature
375:698-700[CrossRef][Medline].
|
| 3.
|
Billeter, M.,
R. Riek,
G. Wider,
S. Hornemann,
R. Glockshuber, and K. Wuthrich.
1997.
Prion protein NMR structure and species barrier for prion diseases.
Proc. Natl. Acad. Sci. USA
94:7281-7285[Abstract/Free Full Text].
|
| 4.
|
Blattler, T.,
S. Brandner,
A. J. Raeber,
M. A. Klein,
T. Voigtlander,
C. Weissmann, and A. Aguzzi.
1997.
PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain.
Nature
389:69-73[CrossRef][Medline].
|
| 5.
|
Bolton, D. C.,
S. J. Seligman,
G. Bablanian,
D. Windsor,
L. J. Scala,
K. S. Kim,
C. M. J. Chen,
R. J. Kascsak, and P. E. Bendheim.
1991.
Molecular location of a species-specific epitope on the hamster scrapie agent protein.
J. Virol.
65:3667-3675[Abstract/Free Full Text].
|
| 6.
|
Bossers, A.,
P. B. G. M. Belt,
G. J. Raymond,
B. Caughey,
R. de Vries, and M. A. Smits.
1997.
Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms.
Proc. Natl. Acad. Sci. USA
94:4931-4936[Abstract/Free Full Text].
|
| 7.
|
Bossers, A.,
R. de Vries, and M. A. Smits.
2000.
Susceptibility of sheep for scrapie as assessed by in vitro conversion of nine naturally occurring variants of PrP.
J. Virol.
74:1407-1414[Abstract/Free Full Text].
|
| 8.
|
Brandner, S.,
S. Isenmann,
A. Raeber,
M. Fischer,
A. Sailer,
Y. Kobayashi,
S. Marino,
C. Weissmann, and A. Aguzzi.
1996.
Normal host prion protein necessary for scrapie-induced neurotoxicity.
Nature
379:339-343[CrossRef][Medline].
|
| 9.
|
Bueler, H.,
A. Aguzzi,
A. Sailer,
R.-A. Greiner,
P. Autenried,
M. Aguet, and C. Weissmann.
1993.
Mice devoid of PrP are resistant to scrapie.
Cell
73:1339-1347[CrossRef][Medline].
|
| 10.
|
Caughey, B.,
D. A. Kocisko,
S. A. Priola,
G. J. Raymond,
R. E. Race,
R. A. Bessen,
P. T. Lansbury, Jr., and B. Chesebro.
1996.
Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems, p. 285-300.
In
H. F. Baker, and R. M. Ridley (ed.), Prion diseases. Humana Press, Totowa, N.J.
|
| 11.
|
Caughey, B.,
R. E. Race, and B. Chesebro.
1988.
Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines.
J. Gen. Virol.
69:711-716[Abstract/Free Full Text].
|
| 12.
|
Caughey, B.,
R. E. Race,
D. Ernst,
M. J. Buchmeier, and B. Chesebro.
1989.
Prion protein (PrP) biosynthesis in scrapie-infected and uninfected neuroblastoma cells.
J. Virol.
63:175-181[Abstract/Free Full Text].
|
| 13.
|
Caughey, B., and G. J. Raymond.
1991.
The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive.
J. Biol. Chem.
266:18217-18223[Abstract/Free Full Text].
|
| 14.
|
Caughey, B.,
G. J. Raymond, and R. A. Bessen.
1998.
Strain-dependent differences in beta-sheet conformations of abnormal prion protein.
J. Biol. Chem.
273:32230-32235[Abstract/Free Full Text].
|
| 15.
|
Caughey, B.,
G. J. Raymond,
D. Ernst, and R. E. Race.
1991.
N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state.
J. Virol.
65:6597-6603[Abstract/Free Full Text].
|
| 16.
|
Chesebro, B.,
K. Wehrly,
B. Caughey,
J. Nishio,
D. Ernst, and R. Race.
1993.
Foreign PrP expression and scrapie infection in tissue culture cell lines.
Dev. Biol. Stand.
80:131-140[Medline].
|
| 17.
|
DebBurman, S. K.,
G. J. Raymond,
B. Caughey, and S. Lindquist.
1997.
Chaperone-supervised conversion of prion protein to its protease-resistant form.
Proc. Natl. Acad. Sci. USA
94:13938-13943[Abstract/Free Full Text].
|
| 18.
|
Goldmann, W.,
T. Martin,
J. Foster,
S. Hughes,
G. Smith,
K. Hughes,
M. Dawson, and N. Hunter.
1996.
Novel polymorphisms in the caprine PrP gene: a codon 142 mutation associated with scrapie incubation period.
J. Gen. Virol.
77:2885-2891[Abstract/Free Full Text].
|
| 19.
|
Hill, A. F.,
S. Joiner,
J. Linehan,
M. Desbruslais,
P. L. Lantos, and J. Collinge.
2000.
Species-barrier-independent prion replication in apparently resistant species.
Proc. Natl. Acad. Sci. USA
97:10248-10253[Abstract/Free Full Text].
|
| 20.
|
Hope, J.,
L. J. D. Morton,
C. F. Farquhar,
G. Multhaup,
K. Beyreuther, and R. H. Kimberlin.
1986.
The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP).
EMBO J.
5:2591-2597[Medline].
|
| 21.
|
Horiuchi, M.,
J. Chabry, and B. Caughey.
1999.
Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.
EMBO J.
18:3193-3203[CrossRef][Medline].
|
| 22.
|
Horiuchi, M.,
S. A. Priola,
J. Chabry, and B. Caughey.
2000.
Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers.
Proc. Natl. Acad. Sci. USA
97:5836-5841[Abstract/Free Full Text].
|
| 23.
|
Hornemann, S.,
C. Korth,
B. Oesch,
R. Riek,
G. Wider,
K. Wuthrich, and R. Glockshuber.
1997.
Recombinant full-length murine prion protein, mPrP(23-231): purification and spectroscopic characterization.
FEBS Lett.
413:277-281[CrossRef][Medline].
|
| 24.
|
Kaneko, K.,
L. Zulianello,
M. Scott,
C. M. Cooper,
A. C. Wallace,
T. L. James,
F. E. Cohen, and S. B. Prusiner.
1997.
Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation.
Proc. Natl. Acad. Sci. USA
94:10069-10074[Abstract/Free Full Text].
|
| 25.
|
Kascsak, R. J.,
R. Rubenstein,
P. A. Merz,
M. Tonna-DeMasi,
R. Fersko,
R. I. Carp,
H. M. Wisniewski, and H. Diringer.
1987.
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins.
J. Virol.
61:3688-3693[Abstract/Free Full Text].
|
| 26.
|
Kocisko, D. A.,
J. H. Come,
S. A. Priola,
B. Chesebro,
G. J. Raymond,
P. T. Lansbury, and B. Caughey.
1994.
Cell-free formation of protease-resistant prion protein.
Nature
370:471-474[CrossRef][Medline].
|
| 27.
|
Kocisko, D. A.,
S. A. Priola,
G. J. Raymond,
B. Chesebro,
P. T. Lansbury, Jr., and B. Caughey.
1995.
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier.
Proc. Natl. Acad. Sci. USA
92:3923-3927[Abstract/Free Full Text].
|
| 28.
|
Liu, H.,
S. Farr-Jones,
N. B. Ulyanov,
M. Llinas,
S. Marqusee,
D. Groth,
F. E. Cohen,
S. B. Prusiner, and T. L. James.
1999.
Solution structure of Syrian hamster prion protein rPrP(90-231).
Biochemistry
38:5362-5377[CrossRef][Medline].
|
| 29.
|
Locht, C.,
B. Chesebro,
R. Race, and J. M. Keith.
1986.
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent.
Proc. Natl. Acad. Sci. USA
83:6372-6376[Abstract/Free Full Text].
|
| 30.
|
Oesch, B.,
D. Westaway,
M. Walchli,
M. P. McKinley,
S. B. H. Kent,
R. Aebersold,
R. A. Barry,
P. Tempst,
D. B. Teplow,
L. E. Hood,
S. B. Prusiner, and C. Weissmann.
1985.
A cellular gene encodes scrapie PrP 27 to 30 protein.
Cell
40:735-746[CrossRef][Medline].
|
| 31.
|
Priola, S. A.
1999.
Prion protein and species barriers in the transmissible spongiform encephalopathies.
Biomed. Pharmacother.
53:27-33[CrossRef][Medline].
|
| 32.
|
Priola, S. A.,
B. Caughey,
R. E. Race, and B. Chesebro.
1994.
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells.
J. Virol.
68:4873-4878[Abstract/Free Full Text].
|
| 33.
|
Priola, S. A.,
B. Caughey,
K. Wehrly, and B. Chesebro.
1995.
A 60-kDa prion protein (PrP) with properties of both the normal and scrapie-associated forms of PrP.
J. Biol. Chem.
270:3299-3305[Abstract/Free Full Text].
|
| 34.
|
Priola, S. A., and B. Chesebro.
1995.
A single hamster amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells.
J. Virol.
69:7754-7758[Abstract].
|
| 35.
|
Prusiner, S. B.
1982.
Novel proteinaceous infectious particles cause scrapie.
Science
216:136-144[Abstract/Free Full Text].
|
| 36.
|
Prusiner, S. B.,
M. Scott,
D. Foster,
K. M. Pan,
D. Groth,
C. Mirenda,
M. Torchia,
S. L. Yang,
D. Serban,
G. A. Carlson,
P. C. Hoppe,
D. Westaway, and S. J. DeArmond.
1990.
Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication.
Cell
63:673-686[CrossRef][Medline].
|
| 37.
|
Race, R., and B. Chesebro.
1998.
Scrapie infectivity found in resistant species.
Nature
392:770[CrossRef][Medline].
|
| 38.
|
Race, R. E.,
B. Caughey,
K. Graham,
D. Ernst, and B. Chesebro.
1988.
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones.
J. Virol.
62:2845-2849[Abstract/Free Full Text].
|
| 39.
|
Race, R. E.,
L. H. Fadness, and B. Chesebro.
1987.
Characterization of scrapie infection in mouse neuroblastoma cells.
J. Gen. Virol.
68:1391-1399[Abstract/Free Full Text].
|
| 40.
|
Raymond, G. J.,
A. Bossers,
L. D. Raymond,
K. I. O'Rourke,
L. E. McHolland,
P. K. Bryant III,
M. W. Miller,
E. S. Williams,
M. Smits, and B. Caughey.
2000.
Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease.
EMBO J.
19:4425-4430[CrossRef][Medline].
|
| 41.
|
Raymond, G. J.,
J. Hope,
D. A. Kocisko,
S. A. Priola,
L. D. Raymond,
A. Bossers,
J. Ironside,
R. G. Will,
S. G. Chen,
R. B. Petersen,
P. Gambetti,
R. Rubenstein,
M. A. Smits,
P. T. Lansbury, Jr., and B. Caughey.
1997.
Molecular assessment of the transmissibilities of BSE and scrapie to humans.
Nature
388:285-288[CrossRef][Medline].
|
| 42.
|
Riek, R.,
S. Hornemann,
G. Wider,
M. Billeter,
R. Glockshuber, and K. Wuthrich.
1996.
NMR structure of the mouse prion protein domain PrP(121-231).
Nature
382:180-182[CrossRef][Medline].
|
| 43.
|
Robertson, N. M.,
G. J. Spangrude,
K. Hasenkrug,
L. Perry,
J. Nishio,
K. Wehrly, and B. Chesebro.
1992.
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice.
J. Virol.
66:3271-3277[Abstract/Free Full Text].
|
| 44.
|
Safar, J.,
H. Wille,
V. Itri,
D. Groth,
H. Serban,
M. Torchia,
F. E. Cohen, and S. B. Prusiner.
1998.
Eight prion strains have PrP(Sc) molecules with different conformations.
Nat. Med.
4:1157-1165[CrossRef][Medline].
|
| 45.
|
Scott, M.,
D. Foster,
C. Mirenda,
D. Serban,
F. Coufal,
M. Walchli,
M. Torchia,
D. Groth,
G. Carlson,
S. J. DeArmond,
D. Westaway, and S. B. Prusiner.
1989.
Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques.
Cell
59:847-857[CrossRef][Medline].
|
| 46.
|
Scott, M.,
D. Groth,
D. Foster,
M. Torchia,
S. L. Yang,
S. J. DeArmond, and S. B. Prusiner.
1993.
Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes.
Cell
73:979-988[CrossRef][Medline].
|
| 47.
|
Scott, M. R.,
R. Kohler,
D. Foster, and S. B. Prusiner.
1992.
Chimeric prion protein expression in cultured cells and transgenic mice.
Protein Sci.
1:986-997[Medline].
|
| 48.
|
Stahl, N.,
D. R. Borchelt,
K. Hsiao, and S. B. Prusiner.
1987.
Scrapie prion protein contains a phosphatidylinositol glycolipid.
Cell
51:229-240[CrossRef][Medline].
|
| 49.
|
Telling, G. C.,
M. Scott,
K. K. Hsiao,
D. Foster,
S. L. Yang,
M. Torchia,
K. C. Sidle,
J. Collinge,
S. J. DeArmond, and S. B. Prusiner.
1994.
Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein.
Proc. Natl. Acad. Sci. USA
91:9936-9940[Abstract/Free Full Text].
|
| 50.
|
Will, R. G.,
J. W. Ironside,
M. Zeidler,
S. N. Cousens,
K. Estibeiro,
A. Alperovitch,
S. Poser,
M. Pocchiari,
A. Hofman, and P. G. Smith.
1996.
A new variant of Creutzfeldt-Jakob disease in the UK.
Lancet
347:921-925[CrossRef][Medline].
|
| 51.
|
Williams, E. S., and S. Young.
1980.
Chronic wasting disease of captive mule deer: a spongiform encephalopathy.
J. Wildl. Dis.
16:89-98[Abstract].
|
| 52.
|
Williams, E. S., and S. Young.
1982.
Spongiform encephalopathy of Rocky Mountain elk.
J. Wildl. Dis.
18:465-471[Abstract].
|
Journal of Virology, May 2001, p. 4673-4680, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4673-4680.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
McNally, K. L., Ward, A. E., Priola, S. A.
(2009). Cells Expressing Anchorless Prion Protein Are Resistant to Scrapie Infection. J. Virol.
83: 4469-4475
[Abstract]
[Full Text]
-
Yokoyama, T., Masujin, K., Iwamaru, Y., Imamura, M., Mohri, S.
(2009). Alteration of the biological and biochemical characteristics of bovine spongiform encephalopathy prions during interspecies transmission in transgenic mice models. J. Gen. Virol.
90: 261-268
[Abstract]
[Full Text]
-
Dirikoc, S., Priola, S. A., Marella, M., Zsurger, N., Chabry, J.
(2007). Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity. J. Neurosci.
27: 9537-9544
[Abstract]
[Full Text]
-
Piening, N., Nonno, R., Di Bari, M., Walter, S., Windl, O., Agrimi, U., Kretzschmar, H. A., Bertsch, U.
(2006). Conversion Efficiency of Bank Vole Prion Protein in Vitro Is Determined by Residues 155 and 170, but Does Not Correlate with the High Susceptibility of Bank Voles to Sheep Scrapie in Vivo. J. Biol. Chem.
281: 9373-9384
[Abstract]
[Full Text]
-
Takemura, K., Wang, P., Vorberg, I., Surewicz, W., Priola, S. A., Kanthasamy, A., Pottathil, R., Chen, S. G., Sreevatsan, S.
(2006). DNA Aptamers That Bind to PrPC and Not PrPSc Show Sequence and Structure Specificity. Exp. Biol. Med.
231: 204-214
[Abstract]
[Full Text]
-
Lawson, V. A., Priola, S. A., Meade-White, K., Lawson, M., Chesebro, B.
(2004). Flexible N-terminal Region of Prion Protein Influences Conformation of Protease-resistant Prion Protein Isoforms Associated with Cross-species Scrapie Infection in Vivo and in Vitro. J. Biol. Chem.
279: 13689-13695
[Abstract]
[Full Text]
-
Chesebro, B.
(2003). Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull
66: 1-20
[Abstract]
[Full Text]
-
Vorberg, I., Groschup, M. H., Pfaff, E., Priola, S. A.
(2003). Multiple Amino Acid Residues within the Rabbit Prion Protein Inhibit Formation of Its Abnormal Isoform. J. Virol.
77: 2003-2009
[Abstract]
[Full Text]
-
van Rheede, T., Smolenaars, M. M. W., Madsen, O., de Jong, W. W.
(2003). Molecular Evolution of the Mammalian Prion Protein. Mol Biol Evol
20: 111-121
[Abstract]
[Full Text]
-
Lawson, V. A., Priola, S. A., Wehrly, K., Chesebro, B.
(2001). N-terminal Truncation of Prion Protein Affects Both Formation and Conformation of Abnormal Protease-resistant Prion Protein Generated in Vitro. J. Biol. Chem.
276: 35265-35271
[Abstract]
[Full Text]